Video

Current Treatment Landscape for Patients With PV

Author(s):

Jamile Shammo, MD,Naveen Pemmaraju, MD

Drs Rampal and Yacoub details the currently available treatment options and reviews the rationale for use in patients with PV.

Related Videos
Michael R. Grunwald, MD, FACP
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Daniel DeAngelo, MD, PhD
Related Content
Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Fotograf – stock.adobe.com
November 13th 2024

Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS

Courtney D. DiNardo, MD, MSCE
November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.
November 5th 2024

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in Newly-Diagnosed PV

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute
October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis